Gregg Williams Purchases 1,737,765 Shares of Vivani Medical (NASDAQ:VANI) Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams bought 1,737,765 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was bought at an average cost of $1.14 per share, with a total value of $1,981,052.10. Following the acquisition, the director directly owned 24,826,344 shares of the company’s stock, valued at approximately $28,302,032.16. The trade was a 7.53% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Gregg Williams also recently made the following trade(s):

• On Saturday, November 15th, Gregg Williams purchased 1,737,764 shares of Vivani Medical stock. The shares were purchased at an average cost of $1.14 per share, for a total transaction of $1,981,050.96.
• On Monday, October 27th, Gregg Williams bought 3,703,703 shares of Vivani Medical stock. The shares were bought at an average cost of $1.62 per share, for a total transaction of $5,999,998.86.
• On Wednesday, October 15th, Gregg Williams bought 1,737,764 shares of Vivani Medical stock. The shares were purchased at an average cost of $1.14 per share, with a total value of $1,981,050.96.

Vivani Medical Stock Performance

Shares of VANI opened at $1.40 on Tuesday. The firm has a market cap of $102.13 million, a PE ratio of -3.11 and a beta of 3.24. Vivani Medical, Inc. has a 52-week low of $0.91 and a 52-week high of $1.92. The business’s 50 day moving average price is $1.47 and its two-hundred day moving average price is $1.37.

Vivani Medical (NASDAQ:VANI) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. Research analysts predict that Vivani Medical, Inc. will post -0.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Connective Capital Management LLC increased its position in shares of Vivani Medical by 796.2% in the first quarter. Connective Capital Management LLC now owns 162,098 shares of the company’s stock worth $170,000 after purchasing an additional 144,010 shares during the last quarter. Susquehanna International Group LLP raised its stake in shares of Vivani Medical by 100.5% during the third quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after acquiring an additional 16,200 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Vivani Medical during the third quarter valued at about $26,000. Finally, Panagora Asset Management Inc. purchased a new stake in Vivani Medical during the 2nd quarter valued at $25,000. 6.78% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a research report on Tuesday, October 14th. Zacks Research upgraded shares of Vivani Medical from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 12th. Wall Street Zen raised shares of Vivani Medical to a “sell” rating in a report on Saturday, November 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Vivani Medical in a report on Tuesday, September 2nd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $4.00.

Vivani Medical Company Profile

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.